Patents by Inventor Julie A. Lemm

Julie A. Lemm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20160199355
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: March 11, 2016
    Publication date: July 14, 2016
    Inventors: PIYASENA HEWAWASAM, JOHN F. KADOW, OMAR D. LOPEZ, NICHOLAS A. MEANWELL, YONG TU, ALAN XIANGDONG WANG, NINGNING XU, SAMAYAMUNTHULA VENKATA SATYA ARUN KUMAR GUPTA, POTHUKANURI SRINIVASU, INDASI GOPI KUMAR, PONUGUPATI SURESH KUMAR, MAKONEN BELEMA, ROBERT A. FRIDELL, MIN GAO, JULIE A. LEMM, DONALD R. O'BOYLE, II, JIN-HUA SUN, CHUNFU WANG, YING-KAI WANG
  • Hepatitis C virus inhibitors
    Patent number: 9326973
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: May 3, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, John F. Kadow, Omar D. Lopez, Nicholas A. Meanwell, Yong Tu, Alan Xiangdong Wang, Ningning Xu, Samayamunthula Venkata Satya Arun Kumar Gupta, Pothukanuri Srinivasu, Indasi Gopi Kumar, Ponugupati Suresh Kumar, Makonen Belema, Robert A. Fridell, Min Gao, Julie A. Lemm, Donald R. O'Boyle, II, Jin-Hua Sun, Chunfu Wang, Ying-Kai Wang
  • Combinations of Hepatitis C Virus Inhibitors
    Publication number: 20150335655
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating hepatitis C using such combinations.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 26, 2015
    Inventors: Min Gao, David F. Gardiner, Julie A. Lemm, Fiona McPhee, Stacey A. Voss
  • Combinations of Hepatitis C Virus Inhibitors
    Publication number: 20140235617
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating hepatitis C using such combinations.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Inventors: Min Gao, David F. Gardiner, Julie A. Lemm, Fiona McPhee, Stacey A. Voss
  • Combinations of Hepatitis C Virus Inhibitors
    Publication number: 20130259832
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations.
    Type: Application
    Filed: March 11, 2013
    Publication date: October 3, 2013
    Inventors: Julie A. Lemm, Stacey A. Voss, Min Gao, Susan E. Chaniewski, Amy K. Sheaffer, Fiona McPhee
  • METHODS TO IDENTIFY COMBINATIONS OF NS5A TARGETING COMPOUND THAT ACT SYNERGISTICALLY TO INHIBIT HEPATITIS C VIRUS REPLICATION
    Publication number: 20130157894
    Abstract: The present invention is based on the surprising finding that pairs of HCV NS5A-targeting inhibitors can be identified which display similar resistance profiles yet, when combined, exhibit synergistic inhibition of wild type replicons and/or replicons carrying mutations conferring resistance to the HCV NS5A-targeting inhibitor. In addition, combinations of these molecules result in a higher genetic barrier to resistance, demonstrating their potential utility as novel combination therapies for treatment of HCV.
    Type: Application
    Filed: July 13, 2011
    Publication date: June 20, 2013
    Inventors: Jin-Hua Sun, Min Gao, Donald R. O'Boyle, II, Julie A. Lemm, Susan B. Roberts, Makonen Belema, Nicholas A. Meanwell
  • Combinations of hepatitis C virus inhibitors
    Patent number: 8415374
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: April 9, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Julie A. Lemm, Stacey A. Voss, Min Gao, Susan E. Chaniewski, Amy K. Sheaffer, Fiona McPhee
  • Combinations of Hepatitis C Virus Inhibitors
    Publication number: 20120196794
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating hepatitis C using such combinations.
    Type: Application
    Filed: August 1, 2011
    Publication date: August 2, 2012
    Inventors: Min Gao, David F. Gardiner, Julie A. Lemm, Fiona McPhee, Stacey A. Voss
  • Inhibitors of HCV replication
    Patent number: 8143288
    Abstract: Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: March 27, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Serrano-Wu, Makonen Belema, Lawrence B. Snyder, Nicholas A. Meanwell, Denis R. St. Laurent, Ramesh Kakarla, Van N. Nguyen, Yuping Qiu, Xuejie Yang, John E. Leet, Min Gao, Donald R. O'Boyle, II, Julie A. Lemm, Fukang Yang
  • Combinations of Hepatitis C Virus Inhibitors
    Publication number: 20110250176
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations.
    Type: Application
    Filed: October 7, 2010
    Publication date: October 13, 2011
    Inventors: Julie A. Lemm, Stacey A. Voss, Min Gao, Susan E. Chaniewski, Amy K. Sheaffer, Fiona McPhee
  • Hepatitis C virus assays
    Patent number: 7195885
    Abstract: The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: March 27, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Min Gao, Julie A. Lemm, Donald R. O'Boyle, Peter Nower, Karen Rigat, Jin-hua Sun
  • Iminothiazolidinones as inhibitors of HCV replication
    Patent number: 7183302
    Abstract: Compounds having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: February 27, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey Lee Romine, Scott W. Martin, Lawrence B. Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse, Julie Lemm, Donald O'Boyle, Min Gao, Richard Colonno
  • Inhibitors of HCV replication
    Publication number: 20060276511
    Abstract: Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein.
    Type: Application
    Filed: June 5, 2006
    Publication date: December 7, 2006
    Inventors: Michael Serrano-Wu, Makonen Belema, Lawrence Snyder, Nicholas Meanwell, Denis St. Laurent, Ramesh Kakarla, Van Nguyen, Yuping Qiu, Xuejie Yang, John Leet, Min Gao, Donald O'Boyle, Julie Lemm, Fukang Yang
  • Hepatitis C virus assays
    Publication number: 20050260568
    Abstract: The present invention includes assays useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound, as well as the specificity of that compound for HCV over closely-related viruses (such as Bovine viral diarrhea virus). The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds.
    Type: Application
    Filed: April 29, 2005
    Publication date: November 24, 2005
    Inventors: Min Gao, Julie Lemm, Donald O'Boyle, Peter Nower
  • Iminothiazolidinones as inhibitors of HCV replication
    Publication number: 20050096364
    Abstract: Compounds having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.
    Type: Application
    Filed: August 8, 2003
    Publication date: May 5, 2005
    Inventors: Jeffrey Romine, Scott Martin, Lawrence Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse, Julie Lemm, Donald O'Boyle, Min Gao, Richard Colonno
  • Combination pharmaceutical agents as inhibitors of HCV replication
    Publication number: 20050069522
    Abstract: Disclosed are combination pharmaceutical agents for the treatment of an HCV infection comprising a compound effective to inhibit the function of the HCV NS5A protein and another compound having anti-HCV activity. Compounds which can inhibit the function of the NS5A protein having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The other compounds having anti-HCV activity are effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH and a nucleoside analog for the treatment of an HCV infection.
    Type: Application
    Filed: August 8, 2003
    Publication date: March 31, 2005
    Inventors: Richard Colonno, Julie Lemm, Donald O'Boyle, Min Gao, Jeffrey Romine, Scott Martin, Lawrence Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse
  • Hepatitis C virus assays
    Publication number: 20040121975
    Abstract: The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.
    Type: Application
    Filed: August 12, 2003
    Publication date: June 24, 2004
    Inventors: Min Gao, Julie A. Lemm, Donald R. O'Boyle, Peter Nower, Karen Rigat, Jin-Hua Sun